Cardiotoxicity and Cardiac Monitoring Among Anthracycline-Treated Cancer Patients: A Retrospective Cohort Study

References

• Hortobágyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs. 1997;54(Suppl 4):1–7. doi:10.2165/00003495-199700544-00003
   PubMed Web of Science ®Google Scholar
• Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337. doi:10.1186/1471-2407-10-33720587042
   PubMed Web of Science ®Google Scholar
• Livshits Z, Rao RB, Smith SW. An approach to chemotherapy-associated toxicity. Emerg Med Clin North Am. 2014;32(1):167–203. doi:10.1016/j.emc.2013.09.00224275174
   PubMed Web of Science ®Google Scholar
• Leong SL, Chaiyakunapruk N, Lee SWH. Antineoplastic-related cardiovascular toxicity: a systematic review and meta-analysis in Asia. Crit Rev Oncol Hematol. 2019;141:95–101. doi:10.1016/j.critrevonc.2019.05.01731272046
   PubMed Web of Science ®Google Scholar
• Simůnek T, Stérba M, Popelová O, Adamcová M, Hrdina R, Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep. 2009;61(1):154–171. doi:10.1016/S1734-1140(09)70018-019307704
   PubMed Web of Science ®Google Scholar
• Ky B, Putt M, Sawaya H, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab [published correction appears in J Am Coll Cardiol. 2016 Mar 22;67(11):1385]. J Am Coll Cardiol. 2014;63(8):809–816. doi:10.1016/j.jacc.2013.10.06124291281
   PubMed Web of Science ®Google Scholar
• Lotrionte M, Biondi-Zoccai G, Abbate A, et al. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol. 2013;112(12):1980–1984. doi:10.1016/j.amjcard.2013.08.02624075281
   PubMed Web of Science ®Google Scholar
• Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27(14):2328–2338. doi:10.1200/JCO.2008.21.142519332714
   PubMed Web of Science ®Google Scholar
• Dazzi H, Kaufmann K, Follath F. Anthracycline-induced acute cardiotoxicity in adults treated for leukaemia. Analysis of the clinico-pathological aspects of documented acute anthracycline-induced cardiotoxicity in patients treated for acute leukaemia at the University Hospital of Zürich, Switzerland, between 1990 and 1996. Ann Oncol. 2001;12(7):963–966. doi:10.1023/a:101119691032511521803
   PubMed Web of Science ®Google Scholar
• Volkova M, Russell R 3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2011;7(4):214–220. doi:10.2174/15734031179996064522758622
   PubMedGoogle Scholar
• Eschenhagen T, Force T, Ewer MS, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2011;13(1):1–10. doi:10.1093/eurjhf/hfq21321169385
   PubMed Web of Science ®Google Scholar
• Baech J, Hansen SM, Lund PE, et al. Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines [published correction appears in Br J Haematol. 2020 Mar;188(5):801]. Br J Haematol. 2018;183(5):717–726. doi:10.1111/bjh.1560330406945
   PubMed Web of Science ®Google Scholar
• Skubitz KM, Blaes AH, Konety SH, Francis GS. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value. Cancer Chemother Pharmacol. 2017;80(4):787–798. doi:10.1007/s00280-017-3420-828856562
   PubMed Web of Science ®Google Scholar
• Reinbolt RE, Patel R, Pan X, et al. Risk factors for anthracycline-associated cardiotoxicity. Support Care Cancer. 2016;24(5):2173–2180. doi:10.1007/s00520-015-3008-y26563179
   PubMed Web of Science ®Google Scholar
• Guenancia C, Lefebvre A, Cardinale D, et al. Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: a systematic review and meta-analysis. J Clin Oncol. 2016;34(26):3157–3165. doi:10.1200/JCO.2016.67.484627458291
   PubMed Web of Science ®Google Scholar
• Hequet O, Le QH, Moullet I, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol. 2004;22(10):1864–1871. doi:10.1200/JCO.2004.06.03315143078
   PubMed Web of Science ®Google Scholar
• Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) [published correction appears in Eur Heart J. 2016 Dec 24]. Eur Heart J. 2016;37(36):2768–2801. doi:10.1093/eurheartj/ehw21127567406
   PubMed Web of Science ®Google Scholar
• Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893–911. doi:10.1200/JCO.2016.70.540027918725
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981–1988. doi:10.1161/CIRCULATIONAHA.114.01377725948538
   PubMed Web of Science ®Google Scholar
• Henry ML, Niu J, Zhang N, Giordano SH, Chavez-MacGregor M. Cardiotoxicity and cardiac monitoring among chemotherapy-treated breast cancer patients. JACC Cardiovasc Imaging. 2018;11(8):1084–1093. doi:10.1016/j.jcmg.2018.06.00530092967
   PubMed Web of Science ®Google Scholar
• Chavez-MacGregor M, Niu J, Zhang N, et al. Cardiac monitoring during adjuvant trastuzumab-based chemotherapy among older patients with breast cancer. J Clin Oncol. 2015;33(19):2176–2183. doi:10.1200/JCO.2014.58.946525964256
   PubMed Web of Science ®Google Scholar
• Hung OY, Brown JR, Dai T, Easley KA, Flowers CR, Parashar S. Pattern of cardiac surveillance among patients with lymphoma receiving anthracycline-based chemotherapy. BMJ Open. 2015;5(10):e008350. doi:10.1136/bmjopen-2015-008350
   PubMed Web of Science ®Google Scholar
• Cardinale D, Ciceri F, Latini R, et al. Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: the International CardioOncology Society-one trial. Eur J Cancer. 2018;94:126–137. doi:10.1016/j.ejca.2018.02.00529567630
   PubMed Web of Science ®Google Scholar
• Owattanapanich W, Owattanapanich N, Kungwankiattichai S, Ungprasert P, Ruchutrakool T. Efficacy and toxicity of idarubicin versus high-dose daunorubicin for induction chemotherapy in adult acute myeloid leukemia: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2018;18(12):814–821.e3. doi:10.1016/j.clml.2018.08.00830241991
   PubMed Web of Science ®Google Scholar
• Curigliano G, Cardinale D, Dent S, et al. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin. 2016;66(4):309–325. doi:10.3322/caac.2134126919165
   PubMed Web of Science ®Google Scholar
• Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of anthracyclines. Front Cardiovasc Med. 2020;7:26. doi:10.3389/fcvm.2020.0002632258060
   PubMed Web of Science ®Google Scholar
• Henriksen PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 2018;104(12):971–977. doi:10.1136/heartjnl-2017-31210329217634
   PubMed Web of Science ®Google Scholar